Company: MIRA
Filing Date: 2025-06-17
Form Type: PREM14A
Source: 0001641172-25-015340
Chunk: 0

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-06-17
Form: PREM14A
Chunk 0
---
<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934</div>

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

| ☒ | Preliminary                                                       
 Proxy Statement                                                   |
| ☐ | Confidential,                                                     
 for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| ☐ | Definitive                                                        
 Proxy Statement                                                   |
| ☐ | Definitive                                                        
 Additional Materials                                              |
| ☐ | Soliciting                                                        
 Material under §240.14a-12                                        |

<div align='center'>MIRA Pharmaceuticals, Inc.

(Exact name of Registrant as specified in its charter)</div>

Payment of Filing Fee (Check the appropriate box)

| ☐ | No                                                                                              
 fee required                                                                                    |
| ☐ | Fee                                                                                             
 paid previously with preliminary materials                                                      |
| ☒ | Fee                                                                                             
 computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |

<div align='center'>PROPOSED ACQUISITION

YOUR VOTE IS VERY IMPORTANT</div>

To the Stockholders of MIRA Pharmaceuticals, Inc.:

You are cordially invited to attend a virtual special meeting of the stockholders of MIRA Pharmaceuticals, Inc., a Florida corporation, which we refer to as “we”, “MIRA”, or the “Company”, which will be held exclusively online via live audio-only webcast on , at Eastern Time, unless postponed or adjourned to a later date. This is an important meeting that affects your investment in MIRA.

MIRA and SKNY Pharmaceuticals, Inc. (“SKNY”) have entered into an Agreement and Plan of Merger and Reorganization, dated June 16, 2025 (the “Merger Agreement”), pursuant to which a wholly owned subsidiary of MIRA will merge with and into SKNY, with SKNY surviving as a wholly owned subsidiary of MIRA (the “Merger”). The Merger will result in a biopharmaceutical company focused on the development and potential commercialization of several novel, potentially first-in-class product candidates targeting multiple therapeutic areas, including smoking cessation, obesity, pain management, depression, post-tra